Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
When idiopathic pulmonary fibrosis (IPF) runs in families, it tends to begin earlier in life and be more severe,…
A less toxic precursor formulation of the chemotherapeutic agent paclitaxel can reduce lung…
The use of oxygen at rest is associated with a greater likelihood of death or lung transplant in people with…
The U.S. Food and Drug Administration has granted breakthrough therapy designation to PRM-151, a compound being investigated for the…